Breakthroughs in Nanomedicine-A World Economic Forum Discussion-Ideas @Davos-WIRED
In this World Economic Forum discussion, the University of Oxford #39;s Dr. Sonia Trigueros challenges the way we think about antibiotics and offers an alternati...
By: WIRED
View original post here:
Breakthroughs in Nanomedicine-A World Economic Forum Discussion-Ideas @Davos-WIRED - Video
Regulatory News:
NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma.
The clinical trial will be presented during the congress session dedicated to sarcoma.
This years ASCO will take place in Chicago from 31 May to 3 June, 2014. The Annual Meeting brings together more than 25,000 oncology professionals from a broad range of clinical research specialties.
The NBTXR3 study was selected from over 5,500 abstracts received by the Scientific Program Committee of ASCO for review.
Laurent Levy, CEO of Nanobiotix said: We are honored that ASCO has invited us to present our NBTXR3 data in front of the international oncology community. This is an encouraging step for our team and our partners and we will continue to develop innovative therapies aimed to improve patient care in the fight against cancer.
About NANOBIOTIX - http://www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Companys first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.
Nanobiotixs lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).
Read the original post:
Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of ...
Looking and Listening to Light from Liposome Nanostructures for Cancer Theranostics
Chair Prof. Dr. Jan Mollenhauer, NanoCAN, University of Southern Denmark, (DK) Speaker: Prof. Dr. Kostas Kostarelos, FRSM, FIoN, FRSA, Chair of Nanomedicine,...
By: TAUVOD
Read more:
Looking and Listening to Light from Liposome Nanostructures for Cancer Theranostics - Video
Panel - The Regulation Environment in Nanomedicine -- The Step to the Last Phase of Translation
Participants: -Dr. Falk Ehmann, Scientific Support and Projects, European Medicines Agency, London (UK) -Dr. Kumiko Sakai-Kato, National Institute of Health ...
By: TAUVOD
Read more here:
Panel - The Regulation Environment in Nanomedicine -- The Step to the Last Phase of Translation - Video
Nanomedicine Against Malaria: Use of Poly-based Nanovectors for the Drug Delivery to Plasmodium
Speaker: Prof. Dr. Xavier Fernndez Busquets, PhD, Barcelona Centre for International Health Research, Research Associate, Institute for Bioengineering of Ca...
By: TAUVOD
Panel - The Horizon of Nanomedicine and Targeted Drug Delivery
"Clinical Nanomedicine Targeted Medicine", The European CLINAM ETPN Summit, June 23-26, 2013.
By: TAUVOD
Read this article:
Panel - The Horizon of Nanomedicine and Targeted Drug Delivery - Video
Cancer Stem Cells as Preferential Target for Personalized Cancer Nanomedicine
Chair: Prof. Dr. Jan Mollenhauer, NanoCAN, University of Southern Denmark, Odense (DK) Session: Targeted and Personalized Cancer Nanomedicine 2 Speaker: Prof...
By: TAUVOD
Link:
Cancer Stem Cells as Preferential Target for Personalized Cancer Nanomedicine - Video
Mining Genome Information for New Starting Points in Personalized Cancer Nanomedicine
Speaker: Prof. Dr. Jan Mollenhauer, NanoCAN, University of Southern Denmark (DK) "Clinical Nanomedicine Targeted Medicine", The European CLINAM ETPN Summ...
By: TAUVOD
Originally posted here:
Mining Genome Information for New Starting Points in Personalized Cancer Nanomedicine - Video
Nanomedicine is the medical application of nanotechnology that will hopefully lead to useful research tools, advanced drug delivery systems, and new ways to treat disease or repair damaged tissues and cells. Drug delivery is currently the most advanced application of nanotechnology in medicine. Nanoscale particles are being developed to improve drug bioavailability, a major limitation in the design of new drugs. Poor bioavailability is especially problematic with newer and still experimental RNA interference therapy. Lipid or polymer-based nanoparticles are taken up by cells due to their small size, rather than being cleared from the body. These nanoparticles can be used to shuttle drugs into cells which may not have accepted the drug on its own. The nanoparticle chaperone may also be able to specifically target certain cell types, possibly reducing toxicity and improving efficacy. Nanoparticles such as quantum dot nanocrystals are the size of a protein molecule or short stretch of DNA. Quantum dots can be engineered to absorb and emit many wavelengths of light with very sharp precision. This makes them ideal for protein-protein interaction studies as they can be linked to molecules to form long-lived probes. They can track biological events by tagging specific proteins or DNA in order to follow their progress through biological pathways. In medicine, quantum dots could be used for diagnostic purposes. Dendrimers are another interesting and powerful use of nanotechnology in medicine. Dendrimers are nanostructured synthetic molecules with a regular branching structure projecting from a central core. Dendrimers form one layer at a time so the size of the dendrimer is determined by the number of synthetic steps. Each dendrimer is usually only a few nanometers wide. The outside layer can be engineered to be composed of specific functional groups that can act as hooks to specifically bind other molecules such as DNA. Dendrimers may act as effective agents for delivering DNA into cells during gene therapy. While viral vectors typically trigger an immune response, in principle, dendrimers should not. Nanorobotics or molecular nanotechnology involves the creation of complex mechanical systems constructed from the molecular level. Richard Feynman was the first to propose using machine tools to make smaller machine tools which can make smaller machine tools down to the atomic level. DNA makes an ideal material for the construction of nanomachines due to its stiffness. The intermolecular interactions of DNA are well-known and can be easily predicted. The self-assembly of DNA further facilitates its use as a construction material. Dr. Nadrian Seeman pioneered the use of DNA as a construction material and can make virtually any regular 3D shape. In 1999 his group succeeded in building the first nanoscale robotic actuator from DNA. DNA and later, nanotubes, have been used to construct molecular tweezers which can be used to physically manipulate nanostructures. Research into the construction of nanomotors has advanced greatly and nanomotors will form an important part of future nanorobots. Carlo Montemagno at Cornell has mutated the central rotating shaft of ATPase to have metal-binding amino acids that allow the ATPase to bind to nanoscale nickel pedestals. A silicon bar 100 nanometers long was bound to the rotor subunit of each ATPase by self-assembly, creating an ATP-powered molecular motor. These nanorobots may eventually form sophisticated cellular factories, used to synthesize drugs, repair damaged DNA, and releasing drugs on command.
View post:
Nanomedicine Research
Nanomedicine: towards development of patient-friendly drug-delivery systems
ES-Cancer Focus Group. Third Journal Club: Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications.
By: Egypt Scholars Inc.
See the original post here:
Nanomedicine: towards development of patient-friendly drug-delivery systems - Video
Ideas @Davos | Sonia Trigueros | Breakthroughs in Nanomedicine
http://www.weforum.org/ Growing tolerance to antibiotics means that there are more people dying of infection than cancer. Breakthrough discoveries in nanomed...
By: World Economic Forum
Read the original post:
Ideas @Davos | Sonia Trigueros | Breakthroughs in Nanomedicine - Video
NANOMEDICINE HANGOUT UNIVERSITY OF MIAMI ARSALAN SHABBIR MD
NanoMedicine Hangout with a University of Miami Dermatologist, Arsalan Shabbir MD, who discusses the role of NanoMedicine in Dermatology.
By: NanoMedicine
Go here to see the original:
NANOMEDICINE HANGOUT UNIVERSITY OF MIAMI ARSALAN SHABBIR MD - Video
nanomedicine nanobiotix itele
By: Laurent L
See the original post:
nanomedicine nanobiotix itele - Video
Brown Symposium XXXVI - Mauro Ferrari: "Nanomedicine and New Societal Horizons"
Southwestern University #39;s Brown Symposium in 2014 examined the scientific foundations and the human dimensions of healing, their interaction, and how both in...
By: Southwestern University
View post:
Brown Symposium XXXVI - Mauro Ferrari: "Nanomedicine and New Societal Horizons" - Video
Nanomedicine, Detto tra Noi, 4 marzo 2014
By: A. Vil
Go here to see the original:
Nanomedicine, Detto tra Noi, 4 marzo 2014 - Video
practicum nanomedicine pws Nicole en jordy
By: Jordy Sak
Continue reading here:
practicum nanomedicine pws Nicole en jordy - Video